Cleveland Clinic Led Trial Shows Drug Effective in 96% of Patients With Recurrent Pericarditis
November 17, 2020
November 17, 2020
CLEVELAND, Ohio, Nov. 17 (TNSJou) -- The Cleveland Clinic issued the following news release:
Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of pericarditis recurrence. The study was published today in the New England Journal of Medicine and presented at the American Heart Association's Scientific Sessions.
Pericarditi . . .
Cleveland Clinic researchers leading a global clinical trial have found that rilonacept, an FDA approved drug for other inflammatory diseases, resolved acute pericarditis episodes and reduced risk of pericarditis recurrence. The study was published today in the New England Journal of Medicine and presented at the American Heart Association's Scientific Sessions.
Pericarditi . . .